Skip to main content

Table 2 Physical function and health-related quality of life through week 100/112

From: Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age

  Patients < 65 years Patients ≥ 65 years
Placebo + MTX ➔ Golimumab + MTX (n = 179) Golimumab + MTX (n = 336) Placebo + MTX
➔ Golimumab + MTX (n = 18)
Golimumab + MTX (n = 59)
Improvement from baseline in HAQ-DI
 Week 14 0.20 ± 0.57 0.50 ± 0.56*** 0.10 ± 0.35 0.50 ± 0.65*
 Week 24 0.22 ± 0.56 0.53 ± 0.62*** 0.07 ± 0.43 0.53 ± 0.71**
 Week 52 0.45 ± 0.60 0.53 ± 0.65 0.11 ± 0.41 0.40 ± 0.63
 Week 100 0.49 ± 0.63 0.55 ± 0.67 0.29 ± 0.56 0.44 ± 0.60
Mean change from baseline in SF-36 PCS
 Week 12 3.3 ± 7.4 5.9 ± 7.5*** 2.1 ± 7.3 6.0 ± 8.7
 Week 24 4.0 ± 7.2 8.2 ± 8.2*** 2.3 ± 8.6 8.9 ± 8.9**
 Week 52 7.1 ± 8.0 8.2 ± 8.8 4.4 ± 8.7 7.4 ± 8.9
 Week 112 7.2 ± 8.7 7.7 ± 9.0 5.7 ± 6.3 6.8 ± 10.1
Mean change from baseline in SF-36 MCS
 Week 12 1.6 ± 10.2 5.3 ± 10.0*** 0.02 ± 5.80 2.9 ± 11.5
 Week 24 1.2 ± 10.3 7.1 ± 10.2*** 1.7 ± 7.6 6.0 ± 10.7
 Week 52 4.1 ± 11.4 7.1 ± 11.0 2.0 ± 9.2 5.8 ± 12.2
 Week 112 3.9 ± 11.5 6.0 ± 11.3 1.7 ± 9.2 4.4 ± 10.7
  1. All data are presented as mean ± standard deviation
  2. HAQ-DI health assessment questionnaire-disability index, MTX methotrexate, SF-36 PCS/MCS 36-item Short Form Health Survey Physical/Mental Component Summary
  3. *p < 0.05, **p < 0.01, ***p < 0.001